Vafseo is now approved for dialysis patients and leverages AKBA’s signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

Can include rhythm, melody, harmony, dynamics, texture, timbre and structure. of the music such as their melody close melodyDifferent pitched notes played one after another making a tune., ...

Shares of AKBA stock opened at $2.10 on Monday. The stock has a market cap of $458.18 million, a P/E ratio of -9.13 and a beta of 0.74. The company has a fifty day moving average price of $2.01 ...

Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

We have seen 54 institutional investors add shares of AKBA stock to their portfolio, and 39 decrease their positions in their most recent quarter.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Let's be real for a second. Our attention spans aren't what they used to be. With the constant bombardment of content from all sides competing for our glances, our ears, and our fingers, it's no ...